Array's combo for BRAF-positive colon cancer could be a blockbuster, analysts say—but only if it can prove safety and durability.
With Congress railing against insulin list prices, Eli Lilly promised a cheaper generic Humalog in a show of good faith. Consider that promise kept.…
J&J's med should have faced generics years ago, a lawsuit claims, but J&J used underhanded tactics to keep cheaper copycats at bay.
As J&J continues to defend against allegations its talc powders can cause cancer, it prevailed in a South Carolina trial and lost in New York on Tuesday.
Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.
GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.
MTPA, maker of ALS treatment Radicava, has opened up its care locator database to help patients to find healthcare and infusion centers.
Days after ICER called out Spravato for being too costly, developer J&J unveiled its own analysis based on a cost-per-remitter model, arguing the opposite.
Merck & Co.'s Fosamax fight has lasted for years—and now, thanks to a U.S. Supreme Court ruling Monday, Merck gets yet another chance to press its…
Just amid a global retreat of Lartruvo, Eli Lilly's cancer portfolio suffers another setback as Verzenio runs into safety problems in Japan.